Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GALR3 | O60755 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4413954 | 0.78 | RAB9A (0.65) | RAB9AL3MBTL1NPC1CYP19A1SMN1; SMN2 | |
| SCHEMBL4414649 | 0.78 | RAB9A (0.65) | RAB9AL3MBTL1NPC1CYP19A1SMN1; SMN2 | |
| SCHEMBL365088 | 0.78 | TSHR (0.44) | RAB9AL3MBTL1NPC1CYP19A1SMN1; SMN2 | |
| SCHEMBL23291129 | 0.78 | RAB9A (0.78) | RAB9AL3MBTL1NPC1SMN1; SMN2HDAC6 | |
| SCHEMBL31272684 | 0.78 | POLB (0.42) | RAB9AL3MBTL1NPC1HDAC6ALDH1A1 | |
| SCHEMBL2326678 | 0.77 | RAB9A (0.62) | RAB9AL3MBTL1NPC1CYP19A1SMN1; SMN2 | |
| SCHEMBL4413466 | 0.77 | RAB9A (1.00) | RAB9AL3MBTL1NPC1SMN1; SMN2HDAC6 | |
| SCHEMBL28206648 | 0.77 | RAB9A (0.62) | RAB9AL3MBTL1NPC1CYP19A1SMN1; SMN2 | |
| SCHEMBL4405590 | 0.77 | RAB9A (0.62) | RAB9AL3MBTL1NPC1CYP19A1SMN1; SMN2 | |
| SCHEMBL4405605 | 0.76 | HDAC6 (0.68) | RAB9AL3MBTL1NPC1CYP19A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709725-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024233642-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PROGENTOS THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20200369653-A1 | 5-(2,5-BIS(4-CHLORO-2-ISOPROPYLPHENYL)THIOPHEN-3-YL)-1H-TETRAZOLE FOR THE TOPICAL TREATMENT OF BACTERIAL INFECTIONS | DENOVAMED INC. (CA) | 2020-11-26 | — | — | US | disclosed |
| EP-1859782-B1 | Composition for coloring and/or lightening human hair comprising tetrazoles | HENKEL AG & CO KGAA (DE) | 2009-12-30 | — | — | EP | disclosed |
| EP-1859782-A1 | Composition for coloring and/or lightening human hair comprising tetrazoles | Henkel Kommanditgesellschaft auf Aktien (DE) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369653-A1 | 5-(2,5-BIS(4-CHLORO-2-ISOPROPYLPHENYL)THIOPHEN-3-YL)-1H-TETRAZOLE FOR THE TOPICAL TREATMENT OF BACTERIAL INFECTIONS | TLR5, CUTA, IL5 | RAB9A 3330/4885L3MBTL1 2771/4885NPC1 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.